Instrument NameMorphic Holding IncInstrument Symbol(MORF-Q)

Instrument ExchangeNASDAQ

How the airline industry's focus on capacity and being able to supply more flights means fares are low, even in the face of record demand.

September S&P 500 E-Mini futures (ESU24) are up +0.16%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.27% this morning as market participants awaited Federal Reserve Chair Jerome Powell’s congressional testimony for insights into the U.S. interest rate outlook.

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.23%. Stock indexes on Monday settled mixed, with the S&P 500 and Nasdaq 100 posting...

Stocks that traded heavily or had substantial price changes on Monday:

The S&P 500 Index ($SPX ) (SPY ) today is up +0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. Stock indexes today are mixed, with the S&P 500 and Nasdaq 100 posting new...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.05%. Stock indexes today are mildly higher, with the S&P 500 and Nasdaq 100 posting...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.05%. Stock indexes today are mildly higher, with the S&P 500 and Nasdaq 100 posting...

The acquisition gives Eli Lilly access to an experimental drug for types of inflammatory bowel diseases

September S&P 500 E-Mini futures (ESU24) are down -0.06%, and September Nasdaq 100 E-Mini futures (NQU24) are down -0.05% this morning as investors looked ahead to the release of U.S. inflation data, Federal Reserve Chair Jerome Powell’s congressional testimony, and the start of the second-quarter earnings season later in the week.

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...

/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...

Stocks that traded heavily or had substantial price changes on Wednesday: MillerKnoll, Peloton rise; Progress Software, NextEra Energy fall

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.46%. Stocks on Monday recovered from early losses and...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.23%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq ($IUXX ) (QQQ ) is up +0.26%. Stocks are mixed, with the S&P 500 earlier in the day falling to a 3-1/2 month...

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.32%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.33%. Stock index futures this morning are mildly lower, following losses in European stocks, on speculation global central banks will keep interest rates higher for longer to...

The trio all have late-stage therapies with blockbuster potential.

Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership...

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral...

Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas...

Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis  Described new understanding of α4β7-expressing immune cells and...

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral...

MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of...

WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral...

Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year ...